Stocks have rallied 177%, and while calling a top is the easiest thing to do, it might not be the most accurate, Cramer says.
VIDEO ON MSN MONEY
Builders get upgraded at Raymond James, as do several energy stocks at Barclays.
- Anadarko (APC) upgraded to Overweight from Equal Weight at Barclays
- Nexen (NXY) upgraded to Overweight from Equal Weight at Barclays
- Cenovus Energy (CVE) upgraded to Overweight from Equal Weight at Barclays
- Transocean (RIG) upgraded to Hold from Trim at Tudor Pickering
- Navistar (NAV) upgraded to Neutral from Sell at Goldman
- Toll Brothers (TOL) upgraded to Outperform from Market Perform at Raymond James
- D.R. Horton (DHI) upgraded to Outperform from Market Perform at Raymond James
- Lennar (LEN) upgraded to Outperform from Market Perform at Raymond James
The tobacco company expects significant market share gains in Japan, Indonesia, Philippines, South Korea and Vietnam.
PMI expects cigarette volume (outside the U.S.) to increase as much as 1.3% a year over the next five years -- an improved outlook compared with previous forecasts. Philip Morris International competes with British American Tobacco (BTI), Japan Tobacco and Imperial Tobacco Group (IMT) in its various geographical segments.
Investors are cheering a decision by the Federal Reserve to pump cheaper dollars into eurozone banks. Yet this merely treats a symptom, not the disease. And it won't save the euro.
All week, the U.S. stock market was curiously buoyant as the eurozone crisis deepened. Wednesday morning, we learned why: The Federal Reserve, in cooperation with major central banks around the world, reduced the cost of providing dollar liquidity to banks in need from 1% over the rate set in the market to 0.5% over.
This unleashed a surge of buying, short covering, and cheerfulness as initial scans of the headlines seemed to suggest the Fed was riding to Europe's rescue. Not quite.
The Fed is merely postponing the inevitable, treating a symptom (bank funding problem) not the disease (a solvency crisis amongst eurozone governments).
The stock is downgraded to 'underperform' by a prominent analyst who says the company is broken.
On a day when stocks soared, Netflix's (NFLX) drop was particularly jarring.
The stock just can't catch a break after passing $300 in July. Its plunge since then has been breathtaking, with shares closing at $64.53 Wednesday.
The day's fall was triggered largely by a downgrade from one of the more prominent analysts covering the stock. Michael Pachter of Wedbush Morgan said in a research note to investors that the company is broken.
Increasing competition in its core business has forced the company to offer value-add services to augment its product portfolio and protect margins.
Cotendo, a smaller Israeli rival which competes with Akamai for value-added services, was founded in 2008 and launched in March of last year. The company has raised more than $36 million in funding from Sequoia Capital, Benchmark Capital and other investors, and also has the backing of strategic partners such as Citrix, Juniper (JNPR), Google (GOOG) and AT&T (T).
But a few are more likely to sell than others. Here are some names.
By Brian Orelli
Another day, another buyout rumor. Monday, it was Onyx Pharmaceuticals (ONXX) that jumped after Bloomberg said the company was in the early stages of exploring the possibility of putting itself up for sale. Before that it wasAchillion Pharmaceuticals (ACHN). And BioSante Pharmaceuticals (BPAX) before that. The rumor list is a mile long.
Here's a news flash for you: Every public biotech could be sold at any point.
New credit downgrades to a number of banks by S&P and still-negative chart patterns mean Bank of America and Citigroup are still very much out of favor.
By Tom Aspray, MoneyShow.com
After the stock market close on Tuesday, S&P downgraded 15 big banks to reflect the results of its new credit criteria. Though many of the banks had been prepared for a downgrade, others immediately wondered about the impact on a fragile stock market.
The low-volume decline last week followed by Monday’s strong surge has kept the rally from the October lows intact, but it order to reverse the negative momentum, a strong weekly close is needed.
Bargain-shopping will never save us, and spending isn't as strong as some would believe.
By Jeff Reeves, InvestorPlace.com
A lot of hay has been made lately about the return of American consumers and the resurgence of retail. Yes, holiday sales got off to a bang as shoppers spent a record $52.4 billion over the Black Friday weekend -- up 16.4% from 2010. Yes, Cyber Monday sales also blew the virtual doors off, if early projections of $1.2 billion hold true.
But let's not fool ourselves. Unemployment remains above 9%. Serious debt woes continue to plague America and Europe. And the broader economic troubles lurk like an unrepentant Scrooge.
The much-awaited offering of the online gaming company may not be as overpriced as you might expect.
By Suzanne McGee, The Fiscal Times
Got an avid FarmVille player among your family members or Facebook friends? The much-ballyhooed initial public offering of online gaming company Zynga (which counts FarmVille among its offerings) is apparently finally on track for the week before Christmas.
You might want to consider giving shares in the company in the hopes that the FarmVille players on your list will recoup some of what they've paid to Zynga for "gold" and other virtual items.
The increases show that the shipping company is confident in its business and its per-package revenue growth.
The higher rates incorporate a reduction in fuel surcharges, which will fall by one percentage point for ground packages and two percentage points for domestic and international air mail. Freight charges are also set to rise, with next-day air freight and two-day air freight facing an increase of 5.9%. Three-day freight charges will remain unchanged.
If the Supreme Court says yes, it could cost the industry billions.
Labor disputes are common in the auto and airline industries but not so much in the pharmaceutical sector. Yet a dispute between pharmaceutical companies and their drug reps could have such serious implications for the entire industry that both sides petitioned the Supreme Court to take on a current case. On Monday the petition was granted.
The court is now set to decide whether GlaxoSmithKline (GSK) has to pay overtime benefits to its sales representatives. What the court decides will have ramifications for similar cases against other Big Pharmas, including Merck (MRK), Novartis (NVS), Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) to name a few.
Could the social-networking site handle a massive offering all by itself?
According to the Wall Street Journal, Facebook chief financial officer David Ebersman "has told bankers he is skeptical about the value bankers could bring to such a deal." That nugget, courtesy of anonymous sources, was designed to make the masters of the universe who arrange multi-billion dollar deals quake in their $695 Gucci loafers. It probably worked.
Though the insurance company has been facing headwinds, there are long-term reasons for investor optimism.
Aﬂac (AFL) ought to be reveling in its own success. As the top seller of cancer and medical insurance products in Japan, Aﬂac produces predictable cash ﬂows from premiums on these policies.
But the shares have been volatile, reflecting its fight against the currents of Japan’s natural disaster and Europe’s debt crisis.
The company has grown sales 7% and per-share proﬁts 14% over the last year, and expectations are for modest growth in 2012 (8% in sales and 4% in per-share proﬁts).
A coordinated intervention by the world's central banks to pump money and liquidity into the system suggests things in Europe are worse than we thought.
Things are much worse than I thought. For me, that's the real takeaway from this financial D-Day, this worldwide coordination from wealthier countries to help major banks in Europe that were clearly about to go under.
Remember, there were two risks to the situation: credit to the banks and credit to the countries. Apparently the credit had all but dried up for SocGen, for BNPParibas and maybe even for Deutsche Bank (DB). Now that credit will be freed up.
Zacks ranks this specialty retailer a strong buy and expects to see double digit earnings growth this year.
By: Tracey Ryniec
Genesco Inc. (GCO), a specialty shoe and hat retailer, is in the sweet spot for retailing. This Zacks #1 Rank (strong buy) is expected to see double digit earnings growth this year. Shares recently soared to a new multi-year high. But surprisingly, GCO is also a value stock, with a forward P/E of 14.7.
Being involved in retail since 1924, Genesco has seen its share of both good and bad economies. Headquartered in Nashville, it now operates 2,225 footwear and headwear retail stores in the U.S., Canada and Puerto Rico.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The solid report comes a month after the retailer closed all of its Canadian operations.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The stock market finished an upbeat week on a mixed note. The S&P 500 added just over a point, holding its weekly gain at 1.0% while the Nasdaq lost 0.4%.
The major averages began the day on an upbeat note, but relinquished their opening gains during the first 90 minutes of action. The early sentiment was boosted by a better-than-expected nonfarm payrolls report for February (175K versus Briefing.com consensus 163K), but a closer look into the report suggested that ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|